Comments Off on Mycovia Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 VIOLET Studies of Oteseconazole in Patients with Recurrent Vulvovaginal Candidiasis
DURHAM, N.C.–(BUSINESS WIRE)–December 9, 2020 — Mycovia Pharmaceuticals, Inc. (“Mycovia”),
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok